Abstract
Background: The recurrent nature of Bipolar Disorder (BD) is the main cause of disability associated with the illness. Despite the proliferation of drugs approved for the maintenance phase of BD, the relapse rate is still high. The combination of drugs, especially the potentiation of mood-stabilizers with second- generation antipsychotics, may reduce the risk of relapse and rehospitalization. However, studies on the efficacy of specific combinations are scarce.
Case presentation: The clinical case of a 28-year-old woman involuntarily admitted to an Acute Psychiatric Unit is presented. She suffers a manic postpartum episode with mixed and psychotic features. During the hospitalization, she is successfully treated with a combination of lithium plus olanzapine. In the discussion, a concise narrative review of the scientific literature on the efficacy of such a combination in BD is made.
Conclusion: The association of lithium plus olanzapine is one of the combinations with most evidence on its efficacy in BD, especially in mixed-featured episodes. Tolerability concerns should not be an obstacle to its use, although they must be considered.
Keywords: Lithium plus olanzapine, bipolar disorder, combination therapies, maintenance phase, mixed features, postpartum.
Graphical Abstract
[1]
Pini S, de Queiroz V, Pagnin D, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 2005; 15(4): 425-34.
[http://dx.doi.org/10.1016/j.euroneuro.2005.04.011] [PMID: 15935623]
[http://dx.doi.org/10.1016/j.euroneuro.2005.04.011] [PMID: 15935623]
[2]
Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med 2020; 383(1): 58-66.
[http://dx.doi.org/10.1056/NEJMra1906193] [PMID: 32609982]
[http://dx.doi.org/10.1056/NEJMra1906193] [PMID: 32609982]
[3]
Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387(10027): 1561-72.
[http://dx.doi.org/10.1016/S0140-6736(15)00241-X] [PMID: 26388529]
[http://dx.doi.org/10.1016/S0140-6736(15)00241-X] [PMID: 26388529]
[4]
Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers 2018; 4: 18008.
[http://dx.doi.org/10.1038/nrdp.2018.8] [PMID: 29516993]
[http://dx.doi.org/10.1038/nrdp.2018.8] [PMID: 29516993]
[5]
González-Pinto A, Barbeito S, Alonso M, et al. Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. J Clin Psychiatry 2011; 72(5): 671-6.
[http://dx.doi.org/10.4088/JCP.09m05483yel] [PMID: 20868631]
[http://dx.doi.org/10.4088/JCP.09m05483yel] [PMID: 20868631]
[6]
Wingård L, Brandt L, Bodén R, Kieler H, Andersen M, Reutfors J. Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. Eur Neuropsychopharmacol 2019; 29(6): 691-700.
[http://dx.doi.org/10.1016/j.euroneuro.2019.04.003] [PMID: 31078359]
[http://dx.doi.org/10.1016/j.euroneuro.2019.04.003] [PMID: 31078359]
[7]
Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. Am J Psychiatry 2016; 173(2): 117-27.
[http://dx.doi.org/10.1176/appi.ajp.2015.15010124] [PMID: 26514657]
[http://dx.doi.org/10.1176/appi.ajp.2015.15010124] [PMID: 26514657]
[8]
Bjørklund L, Horsdal HT, Mors O, Østergaard SD, Gasse C. Trends in the psychopharmacological treatment of bipolar disorder: A nationwide register-based study. Acta Neuropsychiatr 2016; 28(2): 75-84.
[http://dx.doi.org/10.1017/neu.2015.52] [PMID: 26357986]
[http://dx.doi.org/10.1017/neu.2015.52] [PMID: 26357986]
[9]
Chang CM, Wu CS, Huang YW, Chau YL, Tsai HJ. Utilization of psychopharmacological treatment among patients with newly diagnosed bipolar disorder from 2001 to 2010. J Clin Psychopharmacol 2016; 36(1): 32-44.
[http://dx.doi.org/10.1097/JCP.0000000000000440] [PMID: 26650974]
[http://dx.doi.org/10.1097/JCP.0000000000000440] [PMID: 26650974]
[10]
Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18(2): 174-82.
[http://dx.doi.org/10.1111/bdi.12371] [PMID: 26890465]
[http://dx.doi.org/10.1111/bdi.12371] [PMID: 26890465]
[11]
Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord 2014; 152-154: 12-8.
[http://dx.doi.org/10.1016/j.jad.2013.08.024] [PMID: 24041717]
[http://dx.doi.org/10.1016/j.jad.2013.08.024] [PMID: 24041717]
[12]
Hochman E, Krivoy A, Schaffer A, Weizman A, Vale vs ki A. Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study. Bipolar Disord 2016; 18(8): 684-91.
[http://dx.doi.org/10.1111/bdi.12459] [PMID: 27933713]
[http://dx.doi.org/10.1111/bdi.12459] [PMID: 27933713]
[13]
Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59(1): 62-9.
[http://dx.doi.org/10.1001/archpsyc.59.1.62] [PMID: 11779284]
[http://dx.doi.org/10.1001/archpsyc.59.1.62] [PMID: 11779284]
[14]
Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-45.
[http://dx.doi.org/10.1192/bjp.184.4.337] [PMID: 15056579]
[http://dx.doi.org/10.1192/bjp.184.4.337] [PMID: 15056579]
[15]
Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Mol Psychiatry 2016; 21(8): 1050-6.
[http://dx.doi.org/10.1038/mp.2015.158] [PMID: 26460229]
[http://dx.doi.org/10.1038/mp.2015.158] [PMID: 26460229]
[16]
Wingård L, Bodén R, Brandt L, et al. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. J Affect Disord 2017; 217: 16-23.
[http://dx.doi.org/10.1016/j.jad.2017.03.054] [PMID: 28364619]
[http://dx.doi.org/10.1016/j.jad.2017.03.054] [PMID: 28364619]
[17]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association 2013.
[18]
Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet 2011; 378(9799): 1306-15.
[http://dx.doi.org/10.1016/S0140-6736(11)60873-8] [PMID: 21851976]
[http://dx.doi.org/10.1016/S0140-6736(11)60873-8] [PMID: 21851976]
[19]
Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: Meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36(2): 375-89.
[http://dx.doi.org/10.1038/npp.2010.192] [PMID: 20980991]
[http://dx.doi.org/10.1038/npp.2010.192] [PMID: 20980991]
[20]
Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 2015; 45(2): 299-317.
[http://dx.doi.org/10.1017/S0033291714001305] [PMID: 25036226]
[http://dx.doi.org/10.1017/S0033291714001305] [PMID: 25036226]
[21]
Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry 2019; 24(2): 198-217. b
[http://dx.doi.org/10.1038/s41380-018-0044-2] [PMID: 29679069]
[http://dx.doi.org/10.1038/s41380-018-0044-2] [PMID: 29679069]
[22]
Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012; 22(5): 339-46.
[http://dx.doi.org/10.1016/j.euroneuro.2011.09.008] [PMID: 22000157]
[http://dx.doi.org/10.1016/j.euroneuro.2011.09.008] [PMID: 22000157]
[23]
Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults, part 3: The clinical guidelines. Int J Neuropsychopharmacol 2017; 20(2): 180-95.
[PMID: 27941079]
[PMID: 27941079]
[24]
Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 2018; 19(1): 2-58.
[http://dx.doi.org/10.1080/15622975.2017.1384850] [PMID: 29098925]
[http://dx.doi.org/10.1080/15622975.2017.1384850] [PMID: 29098925]
[25]
Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20(2): 97-170.
[http://dx.doi.org/10.1111/bdi.12609] [PMID: 29536616]
[http://dx.doi.org/10.1111/bdi.12609] [PMID: 29536616]
[26]
González-Pinto A, López-Peña P, Bermúdez-Ampudia C, Vieta E, Martinez-Cengotitabengoa M. Can lithium salts prevent depressive episodes in the real world? Eur Neuropsychopharmacol 2018; 28(12): 1351-9.
[http://dx.doi.org/10.1016/j.euroneuro.2018.09.008] [PMID: 30243681]
[http://dx.doi.org/10.1016/j.euroneuro.2018.09.008] [PMID: 30243681]
[27]
Malhi GS, Fritz K, Elangovan P, Irwin L. Mixed states: Modelling and management. CNS Drugs 2019; 33(4): 301-13.
[http://dx.doi.org/10.1007/s40263-019-00609-3] [PMID: 30712252]
[http://dx.doi.org/10.1007/s40263-019-00609-3] [PMID: 30712252]
[28]
Vieta E, Valentí M. Mixed states in DSM-5: Implications for clinical care, education, and research. J Affect Disord 2013; 148(1): 28-36.
[http://dx.doi.org/10.1016/j.jad.2013.03.007] [PMID: 23561484]
[http://dx.doi.org/10.1016/j.jad.2013.03.007] [PMID: 23561484]
[29]
Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effectiveness of maintenance therapy of lithium vs. other mood stabilizers in monotherapy and in combinations: A systematic review of evidence from observational studies. Bipolar Disord 2018; 20: 419-31.
[http://dx.doi.org/10.1111/bdi.12623] [PMID: 29441712]
[http://dx.doi.org/10.1111/bdi.12623] [PMID: 29441712]
[30]
Severus E, Bauer M, Geddes J. Efficacy and effectiveness of lithium in the long-term treatment of bipolar disorders: An update 2018. Pharmacopsychiatry 2018; 51(5): 173-6.
[http://dx.doi.org/10.1055/a-0627-7489] [PMID: 29898463]
[http://dx.doi.org/10.1055/a-0627-7489] [PMID: 29898463]
[31]
Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review and network meta-analysis. Lancet Psychiatry 2014; 1(5): 351-9.
[http://dx.doi.org/10.1016/S2215-0366(14)70314-1] [PMID: 26360999]
[http://dx.doi.org/10.1016/S2215-0366(14)70314-1] [PMID: 26360999]
[32]
Berk M, Daglas R, Dandash O, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. Br J Psychiatry 2017; 210(6): 413-21.
[http://dx.doi.org/10.1192/bjp.bp.116.186833] [PMID: 28254958]
[http://dx.doi.org/10.1192/bjp.bp.116.186833] [PMID: 28254958]
[33]
Lähteenvuo M, Tanskanen A, Taipale H, et al. Real- world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 2018; 75(4): 347-55.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.4711] [PMID: 29490359]
[http://dx.doi.org/10.1001/jamapsychiatry.2017.4711] [PMID: 29490359]
[34]
Rybakowski JK. Challenging the negative perception of lithium and optimizing its long-term administration. Front Mol Neurosci 2018; 11: 349.
[http://dx.doi.org/10.3389/fnmol.2018.00349] [PMID: 30333722]
[http://dx.doi.org/10.3389/fnmol.2018.00349] [PMID: 30333722]
[35]
Bergink V, Burgerhout KM, Koorengevel KM, et al. Treatment of psychosis and mania in the postpartum period. Am J Psychiatry 2015; 172(2): 115-23.
[http://dx.doi.org/10.1176/appi.ajp.2014.13121652] [PMID: 25640930]
[http://dx.doi.org/10.1176/appi.ajp.2014.13121652] [PMID: 25640930]
[36]
Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: A systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014; 28(11): 989-1003.
[http://dx.doi.org/10.1007/s40263-014-0197-8] [PMID: 25160685]
[http://dx.doi.org/10.1007/s40263-014-0197-8] [PMID: 25160685]
[37]
Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Diabetes Obes Metab 2019; 21(2): 293-302.
[http://dx.doi.org/10.1111/dom.13522] [PMID: 30187620]
[http://dx.doi.org/10.1111/dom.13522] [PMID: 30187620]
[38]
Nielsen RE, Kessing LV, Nolen WA, Licht RW. Lithium and renal impairment: A review on a still hot topic Pharmacopsychiatry 2018; 51(5): 200-5.
[http://dx.doi.org/10.1055/s-0043-125393] [PMID: 29346806]
[http://dx.doi.org/10.1055/s-0043-125393] [PMID: 29346806]
[39]
Schoot TS, Molmans THJ, Grootens KP, et al. Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol 2020; 31: 16-32.
[PMID: 31837914]
[PMID: 31837914]
[40]
Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: A population-based UK cohort study using electronic health records. World Psychiatry 2016; 15(1): 53-8.
[http://dx.doi.org/10.1002/wps.20298] [PMID: 26833609]
[http://dx.doi.org/10.1002/wps.20298] [PMID: 26833609]
[41]
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-62.
[http://dx.doi.org/10.1016/S0140-6736(13)60733-3] [PMID: 23810019]
[http://dx.doi.org/10.1016/S0140-6736(13)60733-3] [PMID: 23810019]
[42]
European Medicines Agency. EMA/375438/2018. New measures to avoid valproate exposure in pregnancy endorsed. Member State representatives agree new restrictions and pregnancy prevention programme. 2018. Available from: https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-new-measures-avoid-valproateexposure-pregnancy-endorsed_en-0.pdf.
[43]
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939.
[44]
Campos P, Carrió M, Vicedo A, et al. Attitude of psychiatrists on the use of olanzapine in clinical practice: A national survey. Psiquiatría Biológica 2020; 27: 3-8.
[http://dx.doi.org/10.1016/j.psiq.2019.11.001]
[http://dx.doi.org/10.1016/j.psiq.2019.11.001]
[45]
Fornaro M, Maritan E, Ferranti R, et al. Lithium exposure during pregnancy and the postpartum period: A systematic review and meta-analysis of safety and efficacy outcomes. Am J Psychiatry 2020; 177(1): 76-92.
[http://dx.doi.org/10.1176/appi.ajp.2019.19030228] [PMID: 31623458]
[http://dx.doi.org/10.1176/appi.ajp.2019.19030228] [PMID: 31623458]
[46]
Zivanovic O. Lithium: A classic drug-Frequently discussed, but, sadly, seldom prescribed! Aust NZJ Psychiatry 2017; 51(9): 886-96.
[http://dx.doi.org/10.1177/0004867417695889] [PMID: 28403623]
[http://dx.doi.org/10.1177/0004867417695889] [PMID: 28403623]
[47]
Pérez de Mendiola X, Hidalgo-Mazzei D, Vieta E, González-Pinto A. Overview of lithium’s use: A nationwide survey. Int J Bipolar Disord 2021; 9(1): 10.
[http://dx.doi.org/10.1186/s40345-020-00215-z] [PMID: 33687600]
[http://dx.doi.org/10.1186/s40345-020-00215-z] [PMID: 33687600]
Article Metrics
13
1